Exdensur (depemokimab) approved by US FDA for the treatment of severe asthma

16 December 2025 - Approval based on SWIFT trials showing significantly lower rate of annualised asthma exacerbations in patients receiving depemokimab ...

Read more →

FDA eliminates major barrier to using real world evidence in drug and device application reviews

15 December 2025 - The US FDA today removed a key limitation on the use of real world evidence used in ...

Read more →

Palvella Therapeutics granted FDA fast track designation for Qtorin 3.9% rapamycin anhydrous gel for the treatment of angiokeratomas

16 December 2025 - Angiokeratomas are characterised by lymphatic-derived skin lesions that can persistently bleed and significantly impact quality of ...

Read more →

Adagene announces FDA fast track designation for muzastotug (ADG126)

16 December 2025 - Adagene today announced that the US FDA has designated muzastotug, in combination with Merck’s anti-PD-1 therapy, Keytruda ...

Read more →

Aldeyra Therapeutics announces PDUFA extension of the new drug application of reproxalap for the treatment of dry eye disease

15 December 2025 - Aldeyra Therapeutics today announced that the US FDA has extended the PDUFA target action date for the ...

Read more →

Historic first in women's sexual health: FDA grants approval for Addyi (flibanserin) in post-menopausal women

15 December 2025 -  Sprout Pharmaceuticals today announced a monumental milestone for women's health: the US FDA has approved Addyi ...

Read more →

Tecvayli and Darzalex Faspro combination selected for Commissioner’s National Priority Voucher Pilot program

15 December 2025 - We are pleased the US FDA has selected the teclistamab MajesTEC-3 supplemental biologics license application to participate ...

Read more →

US FDA approves LIB Therapeutics’ Lerochol (lerodalcibep-liga) for adults with elevated LDL-cholesterol

15 December 2025 - Lerochol expected to be available in the US in spring 2026. ...

Read more →

Sentynl Therapeutics announces FDA acceptance of CUTX-101 NDA resubmission

15 December 2025 - Sentynl Therapeutics today announced that the US FDA has accepted the resubmission of its new drug ...

Read more →

FDA approves fam-trastuzumab deruxtecan-nxki with pertuzumab for unresectable or metastatic HER2-positive breast cancer

15 December 2025 - Today, the FDA approved fam-trastuzumab deruxtecan-nxki (Enhertu, Daiichi Sankyo) in combination with pertuzumab for the first-line ...

Read more →

US FDA approves Daybue STIX (trofinetide) for oral solution, a new powder formulation, for Rett syndrome

15 December 2025 - Neuren Pharmaceuticals today announced that its partner Acadia Pharmaceuticals has received US FDA approval of Daybue ...

Read more →

Milestone receives FDA approval of Cardamyst (etripamil) as first and only self-administered nasal spray for adults with paroxysmal supraventricular tachycardia

12 December 2025 - First FDA approved treatment in 30+ years for more than 2 million Americans with paroxysmal supraventricular tachycardia. ...

Read more →

FDA approves two oral therapies to treat gonorrhea

12 February 2025 - Approvals are for uncomplicated urogenital gonorrhea. ...

Read more →

BioCryst announces FDA approval of Orladeyo (berotralstat) oral pellets, first and only oral prophylactic treatment for patients with HAE aged 2 to <12 years

12 December 2025 - BioCryst Pharmaceuticals today announced that the US FDA has approved its new drug application for the ...

Read more →

FDA approves niraparib and abiraterone acetate plus prednisone for BRCA2-mutated metastatic castration-sensitive prostate cancer

12 December 2025 - Today, the FDA approved niraparib and abiraterone acetate (Akeega, Janssen Biotech) with prednisone for adults with ...

Read more →